DGAP-Adhoc

4SC AG: 4SC sells operations of its Discovery division - Seite 2

The successful research activities will now continue under the newly
founded BioNTech Small Molecules, constituting a real asset for the entire
BioNTech Group. The innovative technology now enables us to develop
next-generation immunotherapies against cancer also on the basis of
medicinal chemistry. Further, we will use our new research and development
unit to expand and optimize our existing platforms.'

About 4SC

4SC (www.4cs.com) is a biotechnology company dedicated to the research and
development of small-molecule drugs focused on epigenetic mechanisms of
action for the treatment of cancers with high unmet medical needs. These
drugs are intended to provide innovative treatment options that are more
tolerable and efficacious than existing therapies, provide a better quality
of life and offer increased life expectancy. The Company's pipeline
comprises promising products that are in various stages of clinical
development. 4SC's aim is to generate future growth and enhance its
enterprise value by entering into partnerships with pharmaceutical and
biotech companies. Founded in 1997, 4SC had 67 employees at 31 December
2015. 4SC has been listed on the Prime Standard of the Frankfurt Stock
Exchange since December 2005.

About BioNTech

BioNTech (www.biontech.de) is an immunotherapy leader with bench-to-market
capabilities, developing truly personalized, well-tolerated and potent
treatments for cancer and other diseases. Established by clinicians and
scientists, the Group is pioneering disruptive technologies ranging from
individualized mRNA based medicines through innovative chimeric antigen
receptors / T-cell receptor-based products and novel antibody checkpoint
immunomodulators. BioNTech's clinical programs are supported by an in-house
molecular diagnostics unit. Founded in 2008, BioNTech is privately held,
with the Strüngmann Family Office acting as the majority shareholder.

Forward-looking information

This ad hoc release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this ad hoc release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the
future and as a result of which the actual results and performance may
differ substantially from the expected future results or performance
expressed or implied in the forward looking statements. No warranties or
representations are made as to the accuracy, achievement or reasonableness
of such statements, estimates or projections, and 4SC AG has no obligation
to update any such information or to correct any inaccuracies herein or
omission herefrom which may become apparent.

More information about 4SC

4SC AG
Corporate Communications & Investor Relations
Wolfgang Güssgen, [e-mail], [phone]
Dr. Anna Niedl, [e-mail], [phone]

MC Services
Katja Arnold, [e-mail], [phone]

The Trout Group
Chad Rubin, [e-mail], [phone]


More information about BioNTech

BioNTech AG
Communications & Media Relations
Regina Jehle, [e-mail], [phone]

Hume Brophy
Mary Clark, Eva Haas, Hollie Vile, [e-mail], [phone]
5813

29.04.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Planegg-Martinsried
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.4sc.com
ISIN: DE000A14KL72
WKN: A14KL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart,
Tradegate Exchange

End of Announcement DGAP News-Service

---------------------------------------------------------------------------